抗血栓药物疗效存在显著个体差异。PI3Kβ是近年来血小板研究的重要进展，参与了血小板激活、聚集关键环节，但它的作用机理还远未阐明。申请人发现PI3Kβ基因多态性与抗血小板药物药效相关，同时与血小板膜受体GPIIb/IIIa、PEAR1基因多态性有关联作用。据此，申请者推测PI3Kβ基因多态性可能在血小板功能和抗血小板药效个体差异中发挥了重要作用。我们拟在前期研究的基础上，分析健康人群、患者PI3Kβ遗传变异的分布特征，从基因水平阐明PI3Kβ在血栓性疾病发生中的作用；然后分析PI3Kβ基因型与抗血小板药物普拉格雷、GPIIb/IIIa受体拮抗剂药效的关系，并通过基因敲除小鼠验证SNP的功能；最后观察急性冠脉综合征和动脉血栓的患者中PI3Kβ基因多态性对氯吡格雷药效的影响。本研究有望发现抗血小板药物的基因导向个体化治疗新靶点。

Large interindividual pharmacodynamics variability for antithrombotic treatment is commonly observed,and the newly studies indicate that PI3Kβ may play an eccential role . But the mechanism are not clear. The present program aimed to examine the effects of single-nucleotide polymorphisms (SNPs) in PI3Kβgene PIK3CA base on the results of our previous work in clinical trails and genetics test. Second, compare the genotype distribution difference among different populations. Third, we intended to assess the impact of these SNPs on clopidogrel in patients with acute coronary syndrome. The ultimate goal is to investigate the genotype distribution of PI3Kβgene in Chinese Han population, and to clarify the role of these genotypes in interindividual PD variability for antithrombotic treatment.